Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective

Liver Int. 2015 Jan;35(1):7-8. doi: 10.1111/liv.12679.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy*
  • Hepatitis C / prevention & control*
  • Humans
  • Recurrence
  • Ribavirin / therapeutic use*
  • Sofosbuvir
  • Treatment Outcome
  • Uridine Monophosphate / analogs & derivatives*
  • Uridine Monophosphate / therapeutic use
  • Waiting Lists

Substances

  • Antiviral Agents
  • Ribavirin
  • Uridine Monophosphate
  • Sofosbuvir